论文部分内容阅读
目的检测正常人和细菌性阴道病(BV)患者治疗前后阴道局部细胞因子的变化,探讨乳杆菌活菌制剂对女性生殖道免疫的影响,为阴道微生态平衡与阴道黏膜免疫屏障的关系的研究提供一定的依据。方法用乳杆菌活菌制剂治疗BV,通过酶联免疫吸附试验法即ELISA法来检测BV患者治疗前后及正常健康妇女阴道局部细胞因子sIgA、IL-2、IL-13的水平。结果 sIgA、IL-13水平治疗前组较对照组明显升高(P<0.01),治疗后组较治疗前组水平下降(P<0.05),治疗后组较对照组水平升高(P>0.05);IL-2水平治疗前组较对照组明显降低,治疗后组较治疗前组明显升高(P<0.05),治疗后组较对照组下降(P<0.05)。结论 BV患者阴道局部免疫功能发生了改变;乳杆菌活菌制剂对BV患者阴道局部免疫具调节作用.
Objective To investigate the changes of local cytokines in the vagina before and after treatment in normal subjects and patients with bacterial vaginosis (BV), and to explore the effect of Lactobacillus on the reproductive tract immunity in women and to study the relationship between vaginal microecological balance and vaginal mucosal immune barrier Provide some basis. Methods Live Lactobacillus preparations were used to treat BV, and the levels of sIgA, IL-2 and IL-13 in the vagina were measured by enzyme-linked immunosorbent assay (ELISA) to detect vaginal local vaginal fluid before and after treatment. Results The serum levels of sIgA and IL-13 in pretreatment group were significantly higher than those in control group (P <0.01), and the levels of sIgA and IL-13 in pretreatment group were significantly lower than those in control group (P <0.05) (P <0.05). After treatment, the levels of IL-2 in the treatment group were significantly lower than those in the control group (P <0.05). Conclusion Vaginal local immune function in patients with BV has been changed. Live Lactobacillus preparations can modulate vaginal local immunity in patients with BV.